Biomimetic brain tumor niche regulates glioblastoma cells towards a cancer stem cell phenotype

J Neurooncol. 2018 May;137(3):511-522. doi: 10.1007/s11060-018-2763-2. Epub 2018 Jan 22.

Abstract

Glioblastoma (GBM) is the most malignant primary brain tumor and contains tumorigenic cancer stem cells (CSCs), which support the progression of tumor growth. The selection of CSCs and facilitation of the brain tumor niches may assist the development of novel therapeutics for GBM. Herein, hydrogel materials composed of agarose and hydroxypropyl methyl cellulose (HMC) in different concentrations were established and compared to emulate brain tumor niches and CSC microenvironments within a label-free system. Human GBM cell line, U-87 MG, was cultured on a series of HMC-agarose based culture system. Cell aggregation and spheroids formation were investigated after 4 days of culture, and 2.5% HMC-agarose based culture system demonstrated the largest spheroids number and size. Moreover, CD133 marker expression of GBM cells after 6 days of culture in 2.5% HMC-agarose based culture system was 60%, relatively higher than the control group at only 15%. Additionally, cells on 2.5% HMC-agarose based culture system show the highest chemoresistance, even at the high dose of 500 µM temozolomide for 72 h, the live cell ratio was still > 80%. Furthermore, the results also indicate that the expression of ABCG2 gene was up-regulated after culture in 2.5% HMC-agarose based culture system. Therefore, our results demonstrated that biomimetic brain tumor microenvironment may regulate GBM cells towards the CSC phenotype and expression of CSC characteristics. The microenvironment selection and spheroids formation in HMC-agarose based culture system may provide a label-free CSC selection strategy and drug testing model for future biomedical applications.

Keywords: Brain tumor niche; Cancer stem cells (CSCs); Drug resistance; Human glioblastoma cells; Hydroxypropyl methyl cellulose (HMC).

MeSH terms

  • AC133 Antigen / metabolism
  • Antineoplastic Agents, Alkylating / pharmacology
  • Apoptosis / drug effects
  • Brain Neoplasms* / drug therapy
  • Brain Neoplasms* / metabolism
  • Brain Neoplasms* / pathology
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Drug Resistance, Neoplasm
  • Drug Screening Assays, Antitumor / instrumentation
  • Drug Screening Assays, Antitumor / methods
  • Glioblastoma* / drug therapy
  • Glioblastoma* / metabolism
  • Glioblastoma* / pathology
  • Humans
  • Hydrogels
  • Hypromellose Derivatives
  • Neoplastic Stem Cells* / drug effects
  • Neoplastic Stem Cells* / metabolism
  • Neoplastic Stem Cells* / pathology
  • Sepharose
  • Stem Cell Niche*
  • Temozolomide / pharmacology
  • Tissue Engineering* / instrumentation
  • Tissue Engineering* / methods
  • Tissue Scaffolds
  • Tumor Microenvironment*

Substances

  • AC133 Antigen
  • Antineoplastic Agents, Alkylating
  • Hydrogels
  • PROM1 protein, human
  • Hypromellose Derivatives
  • Sepharose
  • Temozolomide